[Tfeb](/entities/tfeb) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[Tfeb](/entities/tfeb) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@mtorc2017]
<table> [@tfeb2020]
<tr><th>Protein Name</th><td>TFEB (Transcription Factor EB)</td></tr> [@tfeb2018]
<tr><th>Gene</th><td><a href="/genes/tfeb">TFEB</a></td></tr> [@tfeb2019a]
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9UJX0" target="_blank">Q9UJX0</a></td></tr> [@tfeb2021]
<tr><th>PDB Structure</th><td>5W5V, 5W5U</td></tr>
<tr><th>Molecular Weight</th><td>53 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Nucleus (cytoplasm in inactive state)</td></tr>
<tr><th>Protein Family</th><td>MITF/TFE family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">ATAXIA</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-e5a1c16b" style="color:#ce93d8" title="Score: 0.50">TFEB-PGC1α Mitochondrial-Lysosomal Decou...</a><br><a href="/hypothesis/h-e3e8407c" style="color:#ce93d8" title="Score: 0.50">The Mitochondrial-Lysosomal Metabolic Co...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1708 edges</a></td>
</tr>
</table>
</div>
TFEB is a transcription factor belonging to the MITF/TFE (Microphthalmia-associated transcription factor/TFEB/TFE) family. It contains a basic helix-loop-helix (bHLH) leucine zipper domain at its N-terminus responsible for DNA binding, and a transcriptional activation domain at its C-terminus. TFEB forms homodimers or heterodimers with other TFE family members to bind DNA at specific promoter elements (CLEAR sites)[@tfeb2019].
The activity of TFEB is primarily regulated by phosphorylation. Under nutrient-rich conditions, TFEB is phosphorylated by mTORC1 at multiple serine residues (including Ser211), creating a binding site for 14-3-3 proteins that sequester TFEB in the cytoplasm. Upon nutrient starvation or mTORC1 inhibition, TFEB is dephosphorylated and translocates to the nucleus[@mtorc2017].
TFEB is the master regulator of lysosomal biogenesis and [autophagy](/entities/autophagy). It controls the expression of genes containing CLEAR (Coordinated Lysosomal Expression and Regulation) elements in their promoters, including genes encoding lysosomal enzymes (cathepsins), lysosomal membrane proteins (LAMP1/2), and autophagy proteins (LC3, ATG proteins). This coordinated gene program enables cells to increase lysosomal capacity and autophagic flux in response to cellular stress or nutrient deprivation[@tfeb2020].
In the nervous system, TFEB plays crucial roles in neuronal protein homeostasis. It regulates autophagy in [neurons](/entities/neurons) and glial cells, contributing to the clearance of protein aggregates and damaged organelles. TFEB is essential for maintaining neuronal health under conditions of cellular stress.
TFEB activation promotes clearance of [amyloid-beta](/proteins/amyloid-beta) plaques through enhanced autophagy. In AD models, TFEB overexpression reduces amyloid burden and improves cognitive function. TFEB activity is impaired in AD brain, contributing to defective autophagy and accumulation of protein aggregates. TFEB is considered a promising therapeutic target for AD[@tfeb2018].
TFEB-mediated autophagy is crucial for clearing [α-synuclein](/proteins/alpha-synuclein) aggregates in PD. TFEB activation enhances the clearance of toxic protein aggregates and protects dopaminergic neurons. Impaired TFEB activity contributes to α-synuclein accumulation in PD models and patients. Small molecule TFEB activators are being developed as PD therapeutics[@tfeb2019a].
TFEB is a key therapeutic target for lysosomal storage disorders (LSDs). TFEB overexpression or activation can enhance lysosomal biogenesis and partially compensate for deficient lysosomal enzyme activity. This approach has shown promise in models of Gaucher disease, Pompe disease, and other LSDs[@tfeb2021].
Multiple strategies are being developed to activate TFEB for therapeutic purposes:
The study of Tfeb Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate